Search results for "C2"

showing 10 items of 879 documents

Bridge-Induced Translocation between NUP145 and TOP2 Yeast Genes Models the Genetic Fusion between the Human Orthologs Associated With Acute Myeloid …

2017

In mammalian organisms liquid tumors such as acute myeloid leukemia (AML) are related to spontaneous chromosomal translocations ensuing in gene fusions. We previously developed a system named bridge-induced translocation (BIT) that allows linking together two different chromosomes exploiting the strong endogenous homologous recombination system of the yeast Saccharomyces cerevisiae. The BIT system generates a heterogeneous population of cells with different aneuploidies and severe aberrant phenotypes reminiscent of a cancerogenic transformation. In this work, thanks to a complex pop-out methodology of the marker used for the selection of translocants, we succeeded by BIT technology to preci…

P53bridge-induced translocationgene fusionnucleoporinacute myeloid leukemiayeastlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Frontiers in Oncology
researchProduct

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

2019

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1…

PBD Polo box domainMTD maximal tolerance doseCDC25 cell division cycle 25HIF-1α hypoxia-inducible factor 1 αMST microscale thermophoresisIC50 50% inhibition concentrationMFP M phase promoting factorPARP-1 poly(ADP-ribose) polymerase-10302 clinical medicineFOXO forkhead box ONec-1 necrostatin 1CDC2 cell division cycle protein 2 homologGeneral Pharmacology Toxicology and PharmaceuticsMitotic catastropheCDK cyclin-dependent kinase0303 health sciencesChemistryPolo-like kinaseMono-targeted therapyCell cycleBUBR1 budding uninhibited by benzimidazole-related 1Polo box domain030220 oncology & carcinogenesisPLK1 Polo-like kinaseNecroptosisSpindle damagePLK1IHC immunohistochemistryOriginal articleNecroptosisCell cyclePLK1APC/C anaphase-promoting complex/cyclosomePLK3ABC avidin-biotin complexPI propidium iodide03 medical and health sciencesFBS fetal bovine serumPDB Protein Data BankKd the dissociation constantKinase activity030304 developmental biologyAkt/PKB signaling pathwayCell growthlcsh:RM1-950LC3 light chain 3lcsh:Therapeutics. PharmacologyCancer researchDAPKs death-associated protein kinase3-MA 3-methyladenineDAPI 4′6-diamidino-2-phenylindoleSAC spindle assembly checkpointActa Pharmaceutica Sinica B
researchProduct

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoin…

2021

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD-1, PD-L1, BTN3A1, an…

PD-L10301 basic medicineCancer ResearchStromal cellSettore MED/06 - Oncologia MedicaArticle03 medical and health sciencesExon0302 clinical medicineImmune systemButyrophilinPD-L1PD-1Medicineprognostic biomarkerReceptorRC254-282butyrophilinsbiologyGiSTbusiness.industrycirculating immune checkpointsNeoplasms. Tumors. Oncology. Including cancer and carcinogensBTN3A1Antitumor immune response BTN3A1 Butyrophilins Circulating immune checkpoints GIST PD‐1 PD‐L1 Prognostic biomarkerantitumor immune response030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinbusinessGISTCancers
researchProduct

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastat…

2020

Introduction of checkpoint inhibitors resulted in durable responses and improvements in overall survival in advanced RCC patients, but the treatment efficacy is widely variable, and a considerable number of patients are resistant to PD-1/PD-L1 inhibition. This variability of clinical response makes necessary the discovery of predictive biomarkers for patient selection. Previous findings showed that the epigenetic modifications, including an extensive microRNA-mediated regulation of tumor suppressor genes, are key features of RCC. Based on this biological background, we hypothesized that a miRNA expression profile directly identified in the peripheral lymphocytes of the patients before and a…

PD-L10301 basic medicinerenal cell carcinomaCancer Researchmedicine.medical_treatmentLymphocytelcsh:RC254-282Articlepredictive biomarkers03 medical and health sciences0302 clinical medicineRenal cell carcinomaPD-L1PD-1microRNAmedicineEpigeneticsmiRNAmicroRNAbiologybusiness.industrysoluble immune checkpointsImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePredictive biomarker030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchbiology.proteinNivolumabbusinessReprogrammingCancers
researchProduct

PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy

2021

Simple Summary Over the last decade, immunotherapies using antibodies targeting the programmed cell death 1 (PD-1) checkpoint or its ligand, programmed death ligand 1 (PD-L1), have emerged as promising therapeutic strategies against cancer. However, some current limitations include a relatively low rate of “responders”, the high cost of the treatment, and a rare risk of hyper-progression. Currently, the main challenge is, therefore, to improve these therapies, for instance, by using combined approaches. Here, we summarize the accumulating evidence that resveratrol (RSV) plays a role in the modulation of the PD-1/PD-L1 axis in cancer cells, suggesting the potential of therapeutic strategies …

PD-L1Cancer Researchmedicine.medical_treatmentContext (language use)ReviewResveratrolresveratrolchemistry.chemical_compoundImmune systemPD-L1PD-1medicinepolyphenolsRC254-282biologybusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseaseOncologychemistryCancer cellbiology.proteinCancer researchimmunotherapybusinessAdjuvantCancers
researchProduct

Immune Contexture of MMR-Proficient Primary Colorectal Cancer and Matched Liver and Lung Metastases

2021

Simple Summary Metastasis is the main cause for cancer mortality. The most common metastatic sites of colorectal cancer (CRC) are the liver and lungs. Tumour-infiltrating lymphocytes are recognized as beneficial prognostic factors both in primary and metastatic CRC, but less is known about their reciprocal differences. The aim of our study was to evaluate immune microenvironment and its prognostic value in a series of mismatch proficient (pMMR) CRC with matched liver and lung metastases. The proportion of tumours with high immune cell infiltration together with PD-L1-positivity almost doubled in metastases compared to primary tumours. Our study confirmed the prognostic value of high ICS in …

PD-L1kasvaimet3122 Cancerscolorectal cancersuolistosyövätlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3126 Surgery anesthesiology intensive care radiologylcsh:RC254-282Articleetäpesäkkeettumour infiltrating lymphocytesimmuunivastePD-1lymfosyytitmetastases
researchProduct

PRC2 allosteric modulation an alternative strategy in drug discovery for the epigenetic diseases

2018

PRC2 epigenetic diseasea
researchProduct

Non Markovian Behavior of the Boltzmann-Grad Limit of Linear Stochastic Particle Systems

2007

We will review some results which illustrate how the distribution of obstacles and the shape of the characteristic curves influence the convergence of the probability density of linear stochastic particle systems to the one particle probability density associated with a Markovian process in the Boltzmann-Grad asymptotics.

Particle systemPhysicsLorentz gas82C21Applied MathematicsGeneral Mathematicsforce field82C40Markov processlattice gasForce field (chemistry)symbols.namesake60K35Boltzmann constantLinear Boltzmann equationsymbolsStatistical physicsnon MarkovianLinear boltzmann equation
researchProduct

Laser Microdissection of the Alveolar Duct Enables Single-Cell Genomic Analysis

2014

Complex tissues such as the lung are composed of structural hierarchies such as alveoli, alveolar ducts, and lobules. Some structural units, such as the alveolar duct, appear to participate in tissue repair as well as the development of bronchioalveolar carcinoma. Here, we demonstrate an approach to conduct laser microdissection of the lung alveolar duct for single-cell PCR analysis. Our approach involved three steps. The initial preparation used mechanical sectioning of the lung tissue with sufficient thickness to encompass the structure of interest. In the case of the alveolar duct, the precision-cut lung slices were 200µm thick; the slices were processed using near-physiologic conditions…

Pathologymedicine.medical_specialtyCancer ResearchCellmicrofluidicsregenerative medicinealveolar ductlcsh:RC254-282Regenerative medicineAlveolar ductSingle-cell analysisMicroscopymedicinesingle-cell analysisOriginal ResearchLaser capture microdissectionLungChemistryrespiratory systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structuremurine lung gene expressionOncologysignaling networklaser microdissectionLung tissueFrontiers in Oncology
researchProduct

Strong Expression of Chemokine Receptor CXCR4 by Renal Cell Carcinoma Correlates with Advanced Disease

2008

Diverse chemokines and their receptors have been associated with tumor growth, tumor dissemination, and local immune escape. In different tumor entities, the level of chemokine receptorCXCR4 expression has been linked with tumor progression and decreased survival. The aim of this study was to evaluate the influence ofCXCR4 expression on the progression of human renal cell carcinoma.CXCR4 expression of renal cell carcinoma was assessed by immunohistochemistry in 113 patients. Intensity ofCXCR4 expression was correlated with both tumor and patient characteristics. Human renal cell carcinoma revealed variable intensities ofCXCR4 expression. StrongCXCR4 expression of renal cell carcinoma was si…

Pathologymedicine.medical_specialtyChemokineArticle Subjectbiologybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCXCR4lcsh:RC254-282Chemokine receptorOncologyTumor progressionRenal cell carcinomaAdvanced diseasebiology.proteinMedicineImmunohistochemistrybusinessReceptorResearch ArticleJournal of Oncology
researchProduct